Lymphoma News

Nearly 40% of patients who received chimeric antigen receptor T-cell therapy required hospitalization for disease- or treatment-related reasons in the year after infusion, results of a research letter in JAMA Oncology showed.

The use of broad-spectrum antibiotics in the month leading up to chimeric antigen receptor T-cell therapy led to poorer outcomes and increased treatment-related toxicities, study results showed.

The FDA granted priority review to mosunetuzumab for treatment of certain patients with relapsed or refractory follicular lymphoma.

Marco Davila, MD, PhD, has been appointed senior vice president and associate director for translational research at Roswell Park Comprehensive Cancer Center.

When Aparna Surapaneni, MD, began working in Memorial Hermann Health System’s radiation oncology department 6 years ago, she noticed a pull-up bar right outside her office.

The FDA granted orphan drug designation to several therapies in development for oncology indications.

The FDA issued a warning about a potentially increased risk for death or serious adverse effects with duvelisib, an approved blood cancer therapy.

Patients with hematologic malignancies who resided in rural areas had a lower likelihood of death in a hospice facility but higher likelihood of dying in a nursing facility than their urban counterparts, according to study results.

The ideal strategy to treat cancer with cell therapy can vary greatly depending on tumor type.

The FDA approved lisocabtagene maraleucel for treatment of adults with relapsed or refractory large B-cell lymphoma after one prior therapy.